Filtered By:
Drug: Zivast
This page shows you your search results in order of date. This is page number 8.
Order by Relevance | Date
Total 875 results found since Jan 2013.
Effect of Intensive Blood Pressure Control on Carotid Morphology and Hemodynamics in Chinese Patients with Hyperhomocysteinemia-Type Hypertension and High Risk of Stroke.
CONCLUSIONS Intensive blood pressure management could be beneficial for Chinese patients with hyperhomocysteinemia-type hypertension and high risk of stroke.
PMID: 31369520 [PubMed - in process]
Source: Medical Science Monitor - August 3, 2019 Category: Research Tags: Med Sci Monit Source Type: research
Clinical efficacy and safety of statin treatment after carotid artery stenting.
Conclusion: Pre-treatment with statin is an effective and safe strategy to prevent from perioperative complications and to improve postoperative outcomes in patients undergoing CAS.
PMID: 31352800 [PubMed - in process]
Source: Artificial Cells, Nanomedicine and Biotechnology - July 31, 2019 Category: Biotechnology Tags: Artif Cells Nanomed Biotechnol Source Type: research
Impact of ADCY9 Genotype on Response to Anacetrapib.
CONCLUSIONS: The REVEAL trial is the single largest study to date evaluating the ADCY9 pharmacogenetic interaction. It provides no support for the hypothesis that ADCY9 genotype is materially relevant to the clinical effects of the CETP inhibitor anacetrapib. The ongoing dal-GenE study will provide direct evidence as to whether there is any specific pharmacogenetic interaction with dalcetrapib.
CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov Unique Identifier: NCT01252953; URL: http://www.isrctn.com Unique Identifier: ISRCTN48678192; URL: https://www.clinicaltrialsregister.eu Unique Identifier: 2010-0...
Source: Circulation - July 22, 2019 Category: Cardiology Authors: Hopewell JC, Ibrahim M, Hill M, Shaw PM, Braunwald E, Blaustein RO, Bowman L, Landray MJ, Sabatine MS, Collins R, HPS3/TIMI55 - REVEAL Collaborative Group Tags: Circulation Source Type: research
A Multicenter, Randomized, Placebo ‐Controlled Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients With Rheumatoid Arthritis
ConclusionAtorvastatin 40 mg daily is safe and results in a significantly greater reduction of LDL cholesterol level than placebo in patients with RA. The 34% CVE risk reduction is consistent with the Cholesterol Treatment Trialists ’ Collaboration meta‐analysis of statin effects in other populations.
Source: Arthritis and Rheumatology - July 21, 2019 Category: Rheumatology Authors: George D. Kitas,
Peter Nightingale,
Jane Armitage,
Naveed Sattar,
Jill J. F. Belch,
Deborah P. M. Symmons, on behalf of
the TRACE RA Consortium,
George Kitas,
Jill Belch,
Deborah Symmons,
Hawys Williams,
Shobna Vasishta,
Rebecca Storey,
Pete Tags: Original Article Source Type: research
Patient-Associated Characteristics Influencing the Risk for Non-Persistence with Statins in Older Patients with Peripheral Arterial Disease
ConclusionsPatients identified as high risk for non-persistence require special attention aimed at the improvement of their persistence with statin treatment.
Source: Drugs and Aging - June 28, 2019 Category: Geriatrics Source Type: research
Statins in stroke.
Conclusion: Treatment with statins prevents ischemic stroke, especially in patients with high cardiovascular risk and established atherosclerotic disease. It seems that both lipid lowering and pleiotropic effects contribute to these effects.
PMID: 31218948 [PubMed - as supplied by publisher]
Source: Current Medicinal Chemistry - June 18, 2019 Category: Chemistry Authors: Aznaouridis K, Masoura C, Vlachopoulos C, Tousoulis D Tags: Curr Med Chem Source Type: research
microRNA-126 inhibits tube formation of HUVECs by interacting with EGFL7 and down-regulating PI3K/AKT signaling pathway
In conclusion, microRNA-126 inhibited tube formation of HUVECs by interacting with EGFL7 and down-regulating PI3K/AKT signaling pathway.
Source: Biomedicine and Pharmacotherapy - June 4, 2019 Category: Drugs & Pharmacology Source Type: research
microRNA-126 inhibits tube formation of HUVECs by interacting with EGFL7 and down-regulating PI3K/AKT signaling pathway.
In conclusion, microRNA-126 inhibited tube formation of HUVECs by interacting with EGFL7 and down-regulating PI3K/AKT signaling pathway.
PMID: 31170663 [PubMed - as supplied by publisher]
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - June 2, 2019 Category: Drugs & Pharmacology Authors: Li Q, Cheng K, Wang AY, Xu QG, Fu ZF, He SY, Xu PX Tags: Biomed Pharmacother Source Type: research
Preventable Cases of Oral Anticoagulant-Induced Bleeding: Data From the Spontaneous Reporting System
Conclusion: Our findings describe the most reported risk factors for preventability of oral anticoagulant-induced bleedings. These factors may be useful for targeting interventions to improve pharmacovigilance activities in our regional territory and to reduce the burden of medication errors and inappropriate prescription.
Introduction
Oral anticoagulant therapy is widely used for the prevention of stroke and systemic embolism in patients with atrial fibrillation, or for the prevention and treatment of deep vein thrombosis and pulmonary embolism (Raj et al., 1994; Monaco et al., 2017). Oral anticoagulants can be di...
Source: Frontiers in Pharmacology - April 29, 2019 Category: Drugs & Pharmacology Source Type: research
Trial of atorvastatin for the primary prevention of cardiovascular events in patients with rheumatoid arthritis (TRACE RA): A multicenter, randomized, placebo controlled trial
ConclusionAtorvastatin 40mg daily was safe and resulted in significantly greater reduction of LDLc than placebo in patients with RA. The 40% (adjusted) CVE risk reduction is consistent with the Cholesterol Treatment Trialists ’ Collaboration meta‐analysis of statin effects in other populations.This article is protected by copyright. All rights reserved.
Source: Arthritis and Rheumatology - April 14, 2019 Category: Rheumatology Authors: George D. Kitas,
Peter Nightingale,
Jane Armitage,
Naveed Sattar,
Jill J.F. Belch,
Deborah P.M. Symmons,
The TRACE RA consortium,
George Kitas,
Jill Belch,
Deborah Symmons,
Hawys Williams,
Shobna Vasishta,
Rebecca Storey,
Peter Nightingale,
Tags: Full Length Source Type: research
Combining Human Umbilical Cord Blood Cells With Erythropoietin Enhances Angiogenesis/Neurogenesis and Behavioral Recovery After Stroke
In conclusion, our results suggest that hUCBC infusion in combination with EPO administration demonstrates therapeutic efficacy in the treatment of stroke-induced injury by promoting neurogenesis and angiogenesis. Further research that delineates the therapeutic mechanism of systemically administered hUCBC and EPO is required.
Ethics Statement
All experimental procedures involving animals were performed in accordance with the Guide for the Care and Use of Laboratory Animals as adopted and promulgated by the U. S. National Institutes of Health and were approved by CHA University Institutional Animal Care & Use Com...
Source: Frontiers in Neurology - April 9, 2019 Category: Neurology Source Type: research
Statins in Ischemic Stroke Prevention: What Have We Learned in the Post-SPARCL (The Stroke Prevention by Aggressive Reduction in Cholesterol Levels) Decade?
We describe the current status of lipid-lowering therapies for ischemic stroke prevention. The SPARCL trial published in 2006 has been a landmark study in vascular neurology. The trial demonstrated that high-dose atorvastatin prevents recurrent stroke, and led the AHA/ASA to recommend statin therapy for patients with stroke or TIA of atherosclerotic origin.Recent findingsRecently, the J-STARS study demonstrated that therapy with low-dose pravastatin reduced atherothrombotic infarction incidence among patients with prior ischemic stroke. Besides, several trials have shown improved stroke outcomes with non-statin lipid-lower...
Source: Current Treatment Options in Neurology - April 7, 2019 Category: Neurology Source Type: research
HMG-CoA Reductase Inhibitors Attenuate Neuronal Damage by Suppressing Oxygen Glucose Deprivation-Induced Activated Microglial Cells.
Abstract
Ischemic stroke is usually followed by inflammatory responses mediated by microglia. However, the effect of statins on directly preventing posthypoxia microglia inflammatory factors to prevent injury to surrounding healthy neurons is unclear. Atorvastatin and rosuvastatin, which have different physical properties regarding their lipid and water solubility, are the most common HMG-CoA reductase inhibitors (statins) and might directly block posthypoxia microglia inflammatory factors to prevent injury to surrounding neurons. Neuronal damage and microglial activation of the peri-infarct areas were investigate...
Source: Neural Plasticity - March 28, 2019 Category: Neurology Authors: Lu D, Shen L, Mai H, Zang J, Liu Y, Tsang CK, Li K, Xu A Tags: Neural Plast Source Type: research
Atorvastatin in the treatment of lithium-induced nephrogenic diabetes insipidus: the protocol of a randomized controlled trial
Lithium is the gold-standard treatment for bipolar disorder, is highly effective in major depressive disorder, and is being investigated for therapeutic benefits in dementia, stroke, and even cancer. Approximately 350,000 Canadians use lithium and more could benefit. Despite this, clinicians are avoiding lithium, largely due to fear of renal toxicity, including irreversible chronic kidney disease (CKD). Nephrogenic Diabetes Insipidus (NDI) occurs in 20% of lithium users and independently predicts a 2-3 times increased risk of CKD.
Source: The American Journal of Geriatric Psychiatry - February 28, 2019 Category: Geriatrics Authors: Jocelyn Fotso Soh, Gabriela Torres-Platas, Serge Beaulieu, Outi Mantere, Robert Platt, Istvan Mucsi, Sybille Saury, Suzane Renaud, Andrea Levinson, Ana Andreazza, Benoit Mulsant, Daniel Mueller, Ayal Schaffer, Annemiek Dols, Nancy Low, Pablo Cervantes, Na Tags: Poster Number: EI - 48 Source Type: research
Differences in statin utilization and lipid lowering by race, ethnicity, and HIV status in a real-world cohort of persons with human immunodeficiency virus and uninfected persons
ConclusionsAmong PWH with statin indication(s), blacks and Hispanics were less likely than whites to have been prescribed a statin. These racial/ethnic disparities were less pronounced among uninfected persons. There were significant differences in type of statin used for PWH compared to uninfected matched controls. Future efforts addressing disparities in CVD prevention among PWH are warranted.
Source: American Heart Journal - January 25, 2019 Category: Cardiology Source Type: research
